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Background: Patients in neurologic in-patient rehabilitation are at risk of cardio- and cerebrovascular events.
Microalbuminuria (MAU) is frequent and an important risk predictor but has not been validated in in-patient
rehabilitation. We therefore aimed to examine MAU as an indicator of risk and predictor of vascular events in a
prospective study.
Methods: The INSIGHT (INvestigation of patients with ischemic Stroke In neuroloGic reHabiliTation) registry is the
first to provide large scale data on 1,167 patients with acute stroke (< 3 months) that survived the initial phase of
high risk and were undergoing neurologic in-patient rehabilitation. MAU was determined by dipstick-testing and
correlated to baseline clinical variables (stroke-origin, functional impairment, co-morbidity, ankle-brachial-index,
intima-media-thickeness) as well as vascular events after one year of follow-up. Comparisons were made with the χ2
or Mann–Whitney-U Test. Relative risks (RR) with 95% confidence intervals (CI) were estimated using log-binominal
models. To evaluate the association between MAU and new vascular events as well as mortality, we calculated
hazard ratios (HR) using Cox proportional hazard regression.
Results: A substantial proportion of patients was MAU positive at baseline (33.1%). Upon univariate analysis these
patients were about 4 years older (69 vs. 65 years; p < 0.0001), had a slightly higher body mass index (27.8 vs. 27.1
kg/m2; p = 0.03) and increased waist circumference (79.5 vs. 50.4% for women [p < 0.0001] and 46.8 vs. 43.2% for
men [p = 0.04]) and twice as often had diabetes mellitus (41.8 vs. 20.1%; p < 0.0001). Patients with MAU had a similar
NIH stroke scale score (median 3 vs. 3; p = 0.379) but had lower values on the Barthel Index (median 75 vs. 90;
p < 0.001). They had higher rates of atrial fibrillation (RR 1.38; 95% CI 1.09-1.75), coronary artery disease (RR 1.54; 95%
CI 1.18-2.00), heart failure (RR 1.70; 95% CI 1.10-2.60) symptomatic peripheral artery disease (RR 2.30; 95% CI
1.40-3.80) and atherosclerotic stroke etiology (53.7 vs. 35.4%; p < 0.0001). MAU was associated with an increased
intima-media-thickness, decreased ankle-brachial-index and polyvascular disease (RR 1.56; 95%CI 1.31-1.99). The
event rate after a median follow-up of 13 months was 6.7% for fatal or nonfatal stroke, 4.7% for death, and 10.9%
for combined vascular events (stroke, MI, vascular death). The presence of MAU was predictive for vascular events
during the following year (HR for total mortality 2.2; 95% CI 1.3-3.7; HR for cardiovascular events 2.3; 95% 1.2 - 4.4).
Conclusions: INSIGHT demonstrated a significant association between MAU and polyvascular disease and further
supports previous findings that MAU predicts cardio-/cerebrovascular events in patients recovering from ischemic
stroke. This biomarker may also be used in patients during neurologic in-patient rehabilitation, opening a window
of opportunity for early intervention in this patient group at increased risk for recurrent events.* Correspondence: d.sander@mac.com
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Microalbuminuria (MAU) is an established marker for
both renal and cardiovascular risk [1]. It has been also
shown to be indicative of asymptomatic cerebral ische-
mic lacunar infarcts observed on neuroimaging [2].
The relationship between MAU and incident stroke has
been investigated in a number of cross-sectional and
prospective studies with a documented positive corre-
lation between the level of MAU and severity of the
event.[3-8].
MAU is also a frequent finding in several acute clinical
conditions including stroke [9-11]. Turay et al. (52
patients with recent stroke) found, that patients with
MAU after acute stroke scored lower on the Scandi-
navian Stroke Scale than patients without MAU, had a
correlation between the daily excretion of albumin and
the severity of neurological deficit on admission
(r −0.48, p < 0.05), had a lower score on the Barthel
Index on Day 90 (median 65 vs. 100, p < 0.01), and had a
higher 90 day mortality rate as compared to patients
without MAU (45.8% vs. 7.1%) [11]. Slowik et al. (50
patients with recent stroke) also found, in a logistic re-
gression analysis, that MAU was an independent pre-
dictor of 1-year mortality after ischemic stroke (OR 6.0;
95%CI 1.3-27.7) [10]. Available data on the predictive
performance of MAU in patients with recent stroke
therefore are derived from studies with low patient num-
bers [9-11], short follow-up [11], and focussing on those
within 24h of acute stroke [10,11]. None of them has
considered patients in neurologic in-patient rehabilita-
tion within the first 3 months after stroke. These
patients differ from those in acute medical care as they
already survived the initial period with a high risk for
morbidity and mortality.
To our knowledge, the INSIGHT (INvestigation of
patients with ischemic Stroke In neuroloGic reHabiliTa-
tion) registry is the first to provide large scale data on
1,167 patients with acute stroke (< 3 months) that sur-
vived the initial phase of high risk undergoing neuro-
logic in-patient rehabilitation [12]. In this dataset we
aimed to examine (1) the prevalence of MAU, (2) the as-
sociation with polyvascular disease, and (3) the predict-
ive value of MAU for further vascular events.
Methods
Design
A total of 1,167 consecutive adult patients in neurologic
in-patient rehabilitation with acute ischemic stroke (< 3
months) were included into this prospective registry be-
tween May and September 2008 [12]. Patients with
hemorrhagic stroke (n = 212) and those not able to pro-
vide written informed consent (severe aphasia [n = 88];
severe cognitive deficits [n = 58]; retraction of initial
informed consent [n = 41]) were excluded. Ethicalapproval was obtained by the Ethics Committee of Tech-
nical University Munich (Klinikum Rechts der Isar) and
patients provided written informed consent prior to
inclusion.
Data collection
Baseline characteristics, co-morbid disease, physical
examination, laboratory results, prior cardiovascular
events, neurologic assessment (TOAST classification,
NIH-Stroke Scale, Rankin score and Barthel Index) and
concomitant drug use were collected on a standardized
case report form at admission to neurologic in-patient
rehabilitation (study onset). Neurological impairment
and the resulting handicap were scored on the National
Institutes of Health Stroke Scale (NIH-SS) [13], the
modified Rankin scale [14,15], and the Barthel Index
[16]. Microalbuminuria was determined with reagent
strips (MicroalbustixW, Bayer Vital, Leverkusen, Ger-
many). The MicroalbustixW reagent stripes measure cre-
atinine and albumin semi-quantitatively. Based on the
recommendations of the manufacturer albumin was
adjusted to creatinine concentration and MAU presence
was calculated using the provided diagram. There were
no patients on maintenance hemodialysis, peritoneal dia-
lysis, and renal transplantation in our patient cohort.
A central structured follow-up interview via telephone
was performed after a median follow-up of 13 months
(12 to 14 months) by a person blinded to the results of
the other investigations. If the patient was alive and able
to provide information, all data were retrieved from
himself. If the patient had died or not able to provide in-
formation (e.g. due to aphasia), family members were
asked. The interviewer underwent a specific training be-
fore performing interviews. In case of death within the
follow-up period the cause of death (myocardial infarc-
tion, stroke or others) and the date was recorded. For
patients alive at one year it was determined whether they
had any cardiovascular event (myocardial infarction, re-
current stroke or transitory ischemic attack - yes, no and
unknown) including frequency but without a specific
date. Events were only obtained via telephone and not
validated against medical records of the treating phys-
ician. In addition medication, symptoms of stroke, car-
diovascular risk factors and modified Rankin score were
evaluated. This kind of a structured interview has been
tested for validity and reproducibility [17].
Vascular risk factors
Risk factors determined included the following: smoking
status, duration of smoking, arterial hypertension (treat-
ment with antihypertensive medication or documented
blood pressure >140 mm Hg systolic or >90 mm Hg dia-
stolic before admission), hyperlipidemia (treatment with
lipid-lowering medication or total cholesterol level ≥ 200
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drugs or diagnosis of diabetes during hospital stay), body
mass index, prevalent ischemic heart disease [IHD]
(documented by previous myocardial infarction or an-
gina pectoris, bypass surgery, or > 50% angiographic
stenosis of ≥ 1 major coronary artery), cholesterol, and
triglycerides.
ABI and IMT measurements
Ankle-brachial index (ABI), duplex ultrasonography in-
cluding intima-media thickness (IMT), plaques and de-
gree of carotid stenosis were performed on site by
trained personnel. The plaque sum score was calculated
according to Crouse [18]. For calculation of the ABI,
both the lower and higher systolic blood pressure in
each leg was divided by the average systolic pressure in
both arms (except in case there was a discrepancy of ≥
10mmHg between the two arms, only the higher blood
pressure of both arms was used). An ABI ≤ 0.9 using
the lower systolic blood pressure in one leg was con-
sidered indicative of subclinical peripheral artery dis-
ease (PAD) [19].
For the determination of IMT, the common carotid ar-
teries (CCA) were examined in anterior, lateral, and pos-
terior planes as described previously [20]. Experienced
investigators performed the duplex ultrasonography
using a standardized study protocol. The ultrasound data
were stored on digital media, were transferred to the
neurovascular laboratory of the Department of Neur-
ology. The measurements of IMT were performed as
previously described in detail with the use of a
computer-supported image analysis system (Sigmascan-
Pro 5.0, SPSS) [20].
Statistical analyses
A subsample of hospitals were monitored on-site for val-
idity and completeness of data obtained. Data entry into
a validated database was performed in duplicate using
SAS 8.02. Categorical variables are presented as percen-
tages with 95% confidence intervals (CI), and continuous
variable as mean plus standard deviation (SD). Compari-
sons were made with the χ2 or Mann–Whitney-U Test.
Relative risk (RR) with 95% CI was estimated using a uni-
variate log-binominal regression model. For multivari-
able adjustment of RR ratios, variables being significantly
different at baseline (see Table 1 with a p-value < 0.05)
were considered: age, body mass index, diabetes, waist
circumference, systolic blood pressure, total and HDL-
cholesterol, the use of ACEi/ARBs, calcium-antagonists
insulin, oral antidiabetic drugs, differences in the func-
tional status, stroke subtype, coronary artery disease and
symptomatic peripheral artery disease. To evaluate the
association between MAU and new vascular events as
well as mortality, we calculated Hazard ratios (HR) usinga Cox proportional hazard regression model. The pri-
mary endpoint was overall mortality after 1 year; second-
ary endpoints were stroke, MI, and vascular mortality. A
p-value <0.05 was considered statistically significant.Results
Prevalence and patient characteristics
Between the onset of acute stroke and study inclusion at
admission to neurologic in-patient rehabilitation there
was a mean delay of 0.9 ± 0.5 months. A substantial pro-
portion of patients were MAU positive at baseline
(33.1%). Upon univariate analysis these patients were
about 4 years older (69 vs. 65 years; p < 0.0001), had a
slightly higher body mass index (27.8 vs. 27.1 kg/m2;
p = 0.03) and waist circumference (79.5 vs. 50.4% for
women [p < 0.0001] and 46.8 vs. 43.2% for men
[p = 0.04]) and twice as often had diabetes mellitus (41.8
vs. 20.1%; p < 0.0001) (Table 1 and 2). Further differences
were an elevation of systolic blood pressure (136 vs. 132
mmHg; p = 0.017) and lower HDL-cholesterol values (44
vs. 49 mg/dl; p = 0.0002). ACE inhibitors and ARBs were
more frequently prescribed in MAU positive patients
(56.2 vs. 40.9%; p = 0.0002). Neurological assessment of
patients revealed that those with MAU had lower values
on the Barthel Index (median 75 vs. 90; p < 0.001).Co-morbid disease conditions
Patients with MAU had higher rates of atrial fibrillation
(RR 1.38; 95%CI 1.09-1.75), coronary artery disease (RR
1.54; 95%CI 1.18-2.00), heart failure (RR 1.70; 95% 1.10-
2.60) and symptomatic peripheral artery disease (RR
2.30; 95%CI 1.40-3.80) compared to patients without
MAU (Figure 1; unadjusted). MAU was closely corre-
lated with an atherosclerotic origin of stroke (Table 1).
In contrast, MAU positive patients showed a microan-
giopathic or an unknown cause of the stroke according
to the TOAST classification less frequently.Correlations of MAU with ABI and IMT
Given the higher frequency of MAU in patients with an
atherosclerotic origin of stroke, we aimed to assess
whether there was a correlation between MAU and the
extent of atherosclerosis in different vascular beds
(Table 3). We observed that patients with MAU had an
increased IMT and a decreased ABI (<0.9), even after ad-
justment for baseline variables and other parameters
(defined in the legend to Table 3). The detection of
MAU was independently associated with an increased
prevalence of polyvascular disease (IMT> 1 mm and
an ABI <0.9) with an RR of 1.56; (95%CI 1.31-1.99,
p = 0.0001).
Table 1 Baseline characteristics at admission to in-patient rehabilitation and pharmacotherapy of patients with or
without MAU
Total (n = 1,167) MAU (+) (n = 386) MAU (−) (n = 781) p-value
Age, mean years ± SD 66± 11.9 69 ± 11.1 65 ± 12.5 < 0.0001
Male gender (%) 58.1 55.7 59.4 0.33
Body Mass Index (mean kg/m2± SD) 27.5 ± 4.7 27.8 ±5.2 27.1 ±1.5 0.03
Diabetes (%) 34.6 41.8 20.1 < 0.0001
Hypertension (%) 79.3 80.2 78.9 0.09
Hyperlipidemia (%) 80.3 81.3 79.7 0.08
Smoking
Current (%) 18.4 17.7 18.7 0.93
Previous (%) 38.8 39.2 38.7 0.93
mean packs*years ± SD 32.1 ± 26.4 33.1 ± 27.8 31.9 ± 27.1 0.65
Waist circumference (%)
men (%≥ 102 cm) 44.4 46.8 43.2 0.04
women (%≥ 88 cm) 40.9 79.5 50.4 <0.0001
Blood pressure
systolic (mean mmHg± SD) 134± 17 136± 18 132± 17 0.017
diastolic (mean mmHg± SD) 77 ± 11 77 ± 12 77 ± 10 0.75
Laboratory parameters (%)
Total cholesterol (mg/dl) 182± 46 178 ±47 184± 44 0.06
HDL-cholesterol (mg/dl) 48 ± 15 44 ±13 49 ± 17 0.0002
LDL-cholesterol (mg/dl) 107± 17 107± 21 107± 15 0.91
Triglycerides (mg/dl) 146± 71 145± 73 149± 69 0.63
Pharmacotherapy
Lipid lowering agents (%) 64.6 66.1 63.9 0.49
ARB/ACEi (%) 45.9 56.2 40.9 0.0002
Betablocker (%) 46.2 45.2 46.7 0.23
Calciumantagonists (%) 29.9 24.8 27.9 0.09
Insulin 5.6 8.2 4.2 0.0003
Oral antidiabetic drugs 14.3 23.3 9.8 0.0002
Functional assessment
NIH Stroke Scale (median, range) 3 (0–25) 3 (0–20) 3 (0–25) 0.379
Barthel Index (median, range) 85 (0–100) 75 (0–100) 90 (0–100) <0.0001
Origin of Stroke (TOAST)
Large artery atherosclerosis 41.4 53.7 35.4 <0.0001
Cardioembolic 21.8 22 21.6 0.456
Small vessel disease 18.9 13.7 21.4 0.01
Other aetiology 4.5 2.4 5.5 0.234
Undetermined aetiology 13.4 8.2 16.1 0.006
Legend: n, number; SD standard deviation, ARB angiotensin receptor blockers, ACEi, angiotensin converting enzyme inhibitor, NIH National Institutes of Health
*p = 0.003 vs. all patients.
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A follow-up was available in 846 patients (72.5%).
Patients lost to follow-up were significantly older but
not significantly different with regard to other baseline
characteristics. The event rate after a median follow-upof 13 months was 6.7% for fatal or nonfatal stroke and
10.9% for combined vascular events (stroke, MI, vascu-
lar death). 40 out of 846 patients (4.7%) died during
the one year follow up, the most frequent reasons
being stroke (n = 9, 22.5%), malignancy (n = 9, 22.5%),







Age, mean years ± SD 64.2 ± 11.1 73.7 ± 10.9*
Male gender (%) 58.2 56.2
Body Mass Index (mean kg/m2± SD) 27.1 ±4.1 27.9 ±5.1
Diabetes (%) 68.1 65.9
Hypertension (%) 78.1 77.7
Hyperlipidemia (%) 79.5 79.8
Smoking
Current (%) 19.3 20.1
Previous (%) 36.5 36.8
mean packs*years ± SD 31.8 ±26.5 32.9 ±28.5
Waist circumference (%)
men (%≥ 102 cm) 48.1 47.1
women (%≥ 88 cm) 79.4 78.2
Blood pressure
systolic (mean mmHg± SD) 135 ±14.2 133 ±15.2
diastolic (mean mmHg± SD) 78 ±11.4 77 ±11.3
Laboratory parameters (%)
Total cholesterol (mg/dl) 181 ± 46.3 183 ± 47.1
HDL-cholesterol (mg/dl) 46 ± 15.2 48 ± 14.2
LDL-cholesterol (mg/dl) 108 ± 39.8 106 ± 37.8
Triglycerides (mg/dl) 142 ± 70.4 141 ± 70.8
Pharmacotherapy
Lipid lowering agents (%) 63.1 63.9
ARB/ACEi (%) 45.6 43.6
Betablocker (%) 44.7 46.7
Calciumantagonists (%) 26.5 25.9
Insulin 5.4 5.7
Oral antidiabetic drugs 14.3 14.2
Functional assessment
NIH Stroke Scale (median, range) 3.0 (0–25) 3.0 (0–25)
Barthel Index (median, range) 86 (0–100) 87 (0–100)
Origin of Stroke (TOAST)
Large artery atherosclerosis 40.9 40.8
Cardioembolic 22.1 21.9
Small vessel disease 18.5 18.8
Other aetiology 4.6 4.5
Undetermined aetiology 13.9 14.0
Legend: n, number, SD standard deviation, ARB angiotensin receptor blockers,
ACEi angiotensin converting enzyme inhibitor, NIH National Institutes of
Health, *p = 0.003 vs. all patients.
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(n = 3, 7.5%). Other causes were rare (n = 1). For 5
patients no information on the cause of death was
available.The clinical utility of MAU testing to independently
predict vascular events is displayed in Table 4. It was
shown that total (HR 2.2; 95%CI 1.3-3.7) and cardiovas-
cular mortality (HR 2.5; 95%CI 1.4-4.7) as well as cardio-
vascular events such as stroke and myocardial infarction
(HR 2.3; 95% 1.2-4.4) were increased in patients with
MAU.
Discussion
The present analysis demonstrates that MAU is asso-
ciated with a number of vascular risk factors and
co-morbid disease conditions in patients undergoing
neurologic in-patient rehabilitation after ischemic stroke.
These patients already survived the initial high risk
phase after stroke but remain at long-term risk for re-
current vascular events. We were able to show that
MAU is a powerful indicator of atherosclerotic risk in
this patient population and a predictor of vascular
events and mortality within a median 13 months follow-
up. These data reinforce the utility of MAU as a bio-
marker in clinical practice.
Patient population and prevalence of MAU
Prior data on the prevalence of stroke have been
reported by Beamer et al., who demonstrated that MAU
was 3 times more prevalent in patients within 6–8 weeks
after stroke (29%) compared with those without (10%)
[9]. The prevalence of MAU reported by Slowik et al. in
patients within 24h after acute stroke was 46.7% [10].
On admission, these patients had a more severe neuro-
logical deficit and more often had a decreased level of
consciousness. This was well matched by Turaj et al.
who reported a prevalence rate of 46.1% within 24h after
acute stroke and found a correlation between the daily
excretion of albumin and the severity of the neurological
deficit (r =−0.48; p0.05) [11]. In our present analysis 33%
of patients undergoing neurologic in-patient rehabilita-
tion had MAU, which was, upon univariate analysis,
associated with diabetes, age, a high waist circumference,
increased systolic blood pressure and an increased im-
pairment of the activities of daily living.
Co-morbid disease conditions
Patients with MAU had higher rates of atrial fibrillation.
This observation corroborates several previous studies
that showed an association between MAU and an
increased incidence of atrial fibrillation [21,22].On the
other hand, MAU correlated less powerful to a cardi-
oembolic origin of stroke. This finding may be explained
by the fact that majority of patients with atrial fibrilla-
tion in our study took oral anticoagulants during the
follow-up period.
Existing data regarding the association between MAU
and stroke type are controversial. For example, Beamer
Figure 1 Prevalence of co-morbid disease in patients with or without MAU (%) Legend. MAU, microalbuminuria; PAD, peripheral arterial
disease; RR, relative risk; CI, confidence interval.
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subtypes [9]. In contrast, it has been shown that MAU is
related to carotid atherosclerosis [23,24] and these find-
ings corroborate our results of MAU being associated
with large-artery stroke.Table 3 Association between MAU and atherosclerosis in diff
significant differences (p < 0.05) in Table 1)
MAU (+) n= 386 M
ABI (lower value of either ankle BP used)
≤ 0.9 (%) 31.5
<0.6 (%) 10.8
0.6-0.9 (%) 20.7
> 0.9 - 1.5 (%) 66.1
>1.5 (%) 2.4
CCA IMT (mm)
1. Quartile (< 0.75) (%) 14.5
2. Quartile (0.75-0.85) (%) 22.5
3. Quartile (0.85-1.05) (%) 33.7
4. Quartile (>1.05) (%) 29.3
> 1mm (%) 31.1
Polyvascular disease
IMT> 1 mm and ABI≤ 0.9 (%) 13.3
Legend: ABI ankle brachial index, BP blood pressure, CCA common carotid artery, IM
multivariable adjustment of ORs, variables being significantly different at baseline (s
diabetes, waist circumference, systolic blood pressure, total and HDL-cholesterol, th
as well as stroke subtype (TOAST), coronary artery disease and symptomatic periphMAU as an indicator of atherosclerosis
There is a significant association between microalbumi-
nuria and carotid artery intima-media thickness, which
suggests that MAU may be a marker for early develop-
ment of carotid artery atherosclerosis and points to aerent vascular beds (Adjusted for variables with
AU (−) n = 781 (ref.) RR (95%CI)* p-value
23.8 1.32 (1.09-1.61) 0.004
3.4 1.91 (1.55-2.37) 0.0002
20.4 1.01 (0.82-1.24) 0.884
72.6 0.82 (0.69-0.98) 0.027
3.6 0.71 (0.40-0.72) 0.29
24.5 0.63 (0.49-0.89) 0.0002
19.0 1.13 (0.94-1.37) 0.148
32.5 1.04 (0.87-1.23) 0.69
24.1 1.21 (1.00-1.42) 0.054
24.7 1.24 (1.02-1.51) 0.029
6.1 1.56 (1.3-1.99) 0.0001
T intima media thickness, MAU microalbuminuria, RR relative, * For
ee table 1 with a p-value < 0.05) were considered: age, body mass index,
e use of ACEi/ARBs, calciumantagonists and differences in the functional status
eral artery disease as outlined in the methods section.
Table 4 Association between MAU testing and new vascular events using Cox proportional Hazard regression
Events MAU (+) n = 280 MAU (−) n = 566 HR (95%CI) † p-value
Primary endpoint
Total mortality (%) 7.8 3.3 2.2 (1.3-3.7) 0.008
Secondary endpoints
Cardiovascular mortality (%) 5.2 2.8 2.5 (1.4-4.7) 0.002
Cardiovascular events (%)* 8.2 4.1 2.2 (1.32-3-72) 0.003
Stroke (%) 6.1 3.2 2.1 (1.05-4.2) 0.004
Myocardial infarction (%) 2.1 0.9 2.3 (1.2-4.4) 0.008
Legend: * Stroke and/or MI; MAU microalbuminuria, HR Hazard ratio, CI confidence interval; † For multivariable adjustment of HRs, variables being significantly
different at baseline (see Table 1 with a p-value < 0.05) were considered: age, body mass index, diabetes, waist circumference, systolic blood pressure, total and
HDL-cholesterol, the use of ACEi/ARBs, calciumantagonists, insulin, oral antidiabetic drugs and differences in the functional status as well as stroke subtype
(TOAST), coronary artery disease and symptomatic peripheral artery disease as outlined in the methods section.
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atherothrombotic stroke mechanism [2,24-26]. In a
study by Ravera et al. MAU was associated with a higher
carotid IMT (0.94 ± 0.05 vs. 0.75 ± 0.06 mm; p= 0.03)
compared with normoalbuminuric patients with un-
treated essential hypertension [2]. Furtner et al. previ-
ously reported a significant correlation of carotid artery
intima-media thickness with MAU [25]. Recent research
likewise suggested that albuminuria is associated with
increased carotid IMT in Chinese type-2 diabetic
patients even below the traditional cut-off values for
microalbuminuria (low-grade albuminuria) [27]. The
results of our analyses confirm these findings in patients
after recent stroke. These associations persisted even
after adjusting for differences in baseline characteristics.
MAU has previously been shown to be associated with
PAD, more so in non-diabetic than in diabetic patients
[28]. Escobedo et al. recently reported that MAU is an
important predictor of peripheral artery disease (defined
by an ABI ≤ 0.9) in CAD patients from the BARI 2D
study [29]. Our data demonstrate that the detection of
MAU is independently associated with an ABI < 0.9 even
in patients with stroke.
To the best of our knowledge the present study ana-
lysed the association between polyvascular disease
(defined as increased IMT and ABI < 0.9) and MAU for
the first time in stroke patients. We observed a signifi-
cantly increased prevalence of polyvascular disease with
an RR of 1.56 in patients with MAU. It is well known
(e.g. from the REACH registry data) that polyvascular
disease is related to an increased risk of future vascular
events, hospitalisation and mortality [30-32]. Thus, our
data implicate, that the detection of MAU in stroke
patients is an indicator for more advanced atherosclerosis
in different vascular beds and an increased vascular risk.
MAU as a predictor of vascular events within 1 year after
stroke
The ability of MAU to identify patients at high risk for
myocardial infarction, stroke and all cause mortality hasbeen described in a number of cross-sectional and pro-
spective studies, which also usually documented a posi-
tive correlation between the degree of albuminuria and
the severity of the event [3,5,6,33]. MAU is a frequent
finding in several acute cardiovascular events including
stroke and is an independent predictor of 1-year mortal-
ity following acute ischemic stroke [9-11]. In the Tromso
Study [6] a high urinary albumin-creatinine ratio (ACR)
was associated with an increased risk of myocardial in-
farction, stroke, and all-cause mortality after a mean
follow-up about 10 years. Multivariable adjustment
revealed, that this was not related to the presence of the
metabolic syndrome.
In the present study, patients with sub-acute stroke
and MAU had a more than doubled risk of cardiovascu-
lar events including non-fatal stroke or MI and fatal
events (HR 2.2; 95%CI 1.3-3.7 for total mortality) even
after adjusting for several baseline parameters, risk fac-
tors and previous vascular disease. While specificity of
MAU testing was high, sensitivity was low. This may
hint at the necessity of repeated testing as suggested in a
number of guidelines [34].
Limitations
Despite the large number of patients included in our
case series from 15 neurologic rehabilitation centres in
Germany, the present analysis is limited by the fact that
1) We included stroke patients from neurologic rehabili-
tation. This may have led to a selection bias towards
more severe stroke patients due to the German specialty
of sending patients with more severe acute stroke defi-
cits for to in-hospital rehabilitation. 2) Follow-up infor-
mation was obtained from only 72.5% of patients. On
the other hand, the baseline data between the patients
without follow-up are very similar to the patients with
follow-up with no significant differences except for age.
Therefore a relevant bias seems unlikely. 3) Follow-up
was only 13 months. 4) MAU determination was con-
ducted using the MicroalbustixW that measures albumin-
uria and creatinine only semi quantitatively. While the
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be ruled out that some where misclassified. It was re-
cently shown however, that dipstick screening of micro-
albuminuria could be used in a population at risk of
chronic kidney disease [35]. 5) We obtained no informa-
tion on blood glucose or HbA1c. 6) Follow-up informa-
tion including primary and secondary endpoints has
been collected only by telephone and in case of death or
inability of the patient to communicate via family mem-
bers or other third persons. No on-site visit was per-
formed to check validity of obtained outcome data.
Conclusions
INSIGHT demonstrated a significant association between
MAU and polyvascular disease and further supports pre-
vious findings that MAU predicts cardio-/cerebrovascu-
lar events in patients recovering from ischemic stroke.
This biomarker may also be used in patients during
neurologic in-patient rehabilitation, opening a window of
opportunity for early intervention in this patient group
at increased risk for recurrent events.
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